+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA-LNP Formulation Market - Global Forecast 2025-2030- Product Image
RNA-LNP Formulation Market - Global Forecast 2025-2030- Product Image
Sale

RNA-LNP Formulation Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129984
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

RNA lipid nanoparticle (RNA-LNP) formulations are shaping a new standard in nucleic acid delivery, transforming therapeutic development and fostering next-generation vaccine innovation. As advances in lipid chemistry, manufacturing, and computational technologies increase precision and scalability, industry leaders face opportunities and challenges in building resilient, efficient pathways for global RNA-LNP adoption.

Market Snapshot: Growth Trajectory and Adoption Insights

The RNA-LNP market is experiencing notable expansion, supported by a surge in research investments and a pipeline of clinical success stories across gene therapy and vaccine platforms. Innovation in ionizable lipids and phospholipid matrices is elevating delivery efficiency and safety profiles, driving industry confidence. Diverse applications—from infectious disease immunization to rare genetic therapies—position RNA-LNPs for prominent roles in both established and emerging markets.

Scope & Segmentation of the RNA-LNP Market

This report offers a comprehensive overview of the RNA-LNP landscape, categorizing market activity across multiple axes essential for informed decision-making by senior executives in biopharma and allied sectors:

  • Product Types: miRNA (including double and single strand formats), mRNA (nonamplifying and self-amplifying), pDNA (circular and linear), and siRNA (modified and standard variants).
  • Applications: Gene editing (CRISPR, TALEN, ZFN approaches), therapeutics (cardiovascular, oncology, rare diseases), and vaccines (for infectious diseases and oncology immunotherapy).
  • Lipid Compositions: Natural and synthetic cholesterol, ionizable lipids (such as ALC-0315, DLin-MC3-DMA, SM-102), PEG lipids (DMG-PEG, DSPE-PEG), and essential phospholipids (DOPE, DSPC) that impact stability and cellular delivery.
  • End Users: Academic and research institutes, contract development and manufacturing organizations (both tier one and tier two CDMOs), pharmaceutical and biotech enterprises.
  • Charge Properties: Anionic lipids (DOPA, DOPS), cationic types (DOTAP, DOTMA), and neutral forms, each influencing membrane interaction and transfection efficiency.
  • Regional Coverage: Americas (broad U.S. geographic detail, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with major and emerging biopharma hubs), and Asia-Pacific (covering China, India, Japan, Australia, Southeast Asia, and more).
  • Company Developments: Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., Catalent, Inc., Fujifilm Diosynth Biotechnologies, Evonik Industries AG, Croda International Plc, CordenPharma International GmbH, Recipharm AB, Polymun Scientific GmbH.

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • RNA-LNP technology is enabling new drug modalities, expanding therapeutic reach beyond traditional biological and small molecule agents.
  • Process engineering, such as continuous flow microfluidics and in-line analytics, is driving scale-up with improved reproducibility and quality assurance.
  • Regulatory harmonization and risk-based frameworks are simplifying approval processes for RNA-LNP products across major jurisdictions.
  • Collaborative ecosystems—including academic partnerships and CDMO alliances—are accelerating innovation and reducing technical risk in bringing RNA-LNP therapies to market.
  • Manufacturers are leveraging computational modeling and machine learning for rational lipid design, reducing development timelines and boosting delivery performance.
  • Segmented adoption patterns are emerging, with North America, EMEA, and Asia-Pacific all investing in facility development, workforce training, and supply chain localization.

Tariff Impact: Navigating Supply Chain Disruption

The 2025 U.S. tariff adjustments on RNA-LNP raw materials—including synthetic cholesterol, specialized ionizable lipids, and PEGylated lipids—are introducing new strategic considerations for procurement and manufacturing. Organizations must respond by diversifying vendor portfolios, renegotiating contracts, and evaluating the feasibility of domestic lipid synthesis. Larger biopharmaceutical companies with established supply networks may absorb these costs more readily, while smaller firms could face constraints that impact pipeline progression. Additionally, collaborative purchasing and resource sharing among consortia are emerging as pragmatic responses to volatility in raw material pricing.

Methodology & Data Sources

The findings in this report are grounded in a multimethod approach, integrating primary expert consultations with leading formulation scientists, secondary analysis of peer-reviewed literature and industry whitepapers, and robust quantitative data modeling. All insights are peer-reviewed and validated for credibility, ensuring our coverage remains timely and actionable.

Why This Report Matters

  • Equips executive leadership with actionable insights needed to navigate technical, regulatory, and commercial complexities in the RNA-LNP sector.
  • Delivers practical recommendations for enhancing supply chain resilience, accelerating innovation cycles, and optimizing partnerships.
  • Supports informed allocation of resources by identifying critical market segments, regional growth priorities, and emerging risk factors.

Conclusion

RNA-LNP formulation innovation continues to redefine possibilities in advanced therapeutics and vaccines. This report empowers senior leaders to translate detailed, data-driven insights into decisive strategies, ensuring readiness for both emerging challenges and transformative growth opportunities in the global RNA-LNP marketplace.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in next generation ionizable lipids to improve mRNA delivery efficiency
5.2. Implementation of artificial intelligence for predictive LNP formulation design and optimization
5.3. Development of targeted RNA-LNP systems for organ-specific therapeutic delivery applications
5.4. Scale-up strategies for continuous manufacturing of RNA-LNP formulations under GMP conditions
5.5. Innovations in lyophilization and storage stabilization techniques for long-term RNA-LNP shelf life
5.6. Integration of quality-by-design frameworks to streamline RNA-LNP regulatory compliance processes
5.7. Exploration of biodegradable lipid excipients to reduce nanoparticle toxicity and environmental impact
5.8. Emergence of combination vaccine platforms co-encapsulating multiple mRNA antigens in liposomal nanoparticles
5.9. Standardization of in vitro and in vivo assays for lipid nanoparticle biodistribution and safety profiling
5.10. Regulatory harmonization efforts driving global approval pathways for RNA-LNP therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. RNA-LNP Formulation Market, by Product Type
8.1. Introduction
8.2. miRNA
8.2.1. Double Strand miRNA
8.2.2. Single Strand miRNA
8.3. mRNA
8.3.1. Non Amplifying mRNA
8.3.2. Self Amplifying mRNA
8.4. pDNA
8.4.1. Circular DNA
8.4.2. Linear DNA
8.5. siRNA
8.5.1. Modified siRNA
8.5.2. Standard siRNA
9. RNA-LNP Formulation Market, by Application
9.1. Introduction
9.2. Gene Editing
9.2.1. CRISPR Based
9.2.2. TALEN Based
9.2.3. ZFN Based
9.3. Therapeutics
9.3.1. Cardiovascular Therapies
9.3.2. Oncology Therapeutics
9.3.3. Rare Disease Therapeutics
9.4. Vaccines
9.4.1. Infectious Disease
9.4.2. Oncology Vaccines
10. RNA-LNP Formulation Market, by Lipid Composition
10.1. Introduction
10.2. Cholesterol
10.2.1. Natural Cholesterol
10.2.2. Synthetic Cholesterol
10.3. Ionizable Lipid
10.3.1. ALC-0315
10.3.2. DLin-MC3-DMA
10.3.3. SM-102
10.4. PEG Lipids
10.4.1. DMG-PEG
10.4.2. DSPE-PEG
10.5. Phospholipid
10.5.1. DOPE
10.5.2. DSPC
11. RNA-LNP Formulation Market, by End User
11.1. Introduction
11.2. Academic And Research Institutes
11.3. Contract Development And Manufacturing Organizations
11.3.1. Tier One
11.3.2. Tier Two
11.4. Pharmaceutical And Biotech Companies
12. RNA-LNP Formulation Market, by Charge
12.1. Introduction
12.2. Anionic
12.2.1. DOPA
12.2.2. DOPS
12.3. Cationic
12.3.1. DOTAP
12.3.2. DOTMA
12.4. Neutral
13. Americas RNA-LNP Formulation Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa RNA-LNP Formulation Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific RNA-LNP Formulation Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Lonza Group Ltd.
16.3.4. Catalent, Inc.
16.3.5. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
16.3.6. Evonik Industries AG
16.3.7. Croda International Plc
16.3.8. CordenPharma International GmbH
16.3.9. Recipharm AB
16.3.10. Polymun Scientific GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RNA-LNP FORMULATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RNA-LNP FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RNA-LNP FORMULATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RNA-LNP FORMULATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RNA-LNP FORMULATION MARKET: RESEARCHAI
FIGURE 26. RNA-LNP FORMULATION MARKET: RESEARCHSTATISTICS
FIGURE 27. RNA-LNP FORMULATION MARKET: RESEARCHCONTACTS
FIGURE 28. RNA-LNP FORMULATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RNA-LNP FORMULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RNA-LNP FORMULATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RNA-LNP FORMULATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOUBLE STRAND MIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOUBLE STRAND MIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SINGLE STRAND MIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SINGLE STRAND MIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CIRCULAR DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CIRCULAR DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LINEAR DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MODIFIED SIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY MODIFIED SIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY STANDARD SIRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY STANDARD SIRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CRISPR BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CRISPR BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TALEN BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TALEN BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ZFN BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ZFN BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CARDIOVASCULAR THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CARDIOVASCULAR THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ONCOLOGY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ONCOLOGY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY RARE DISEASE THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY RARE DISEASE THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ONCOLOGY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ONCOLOGY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NATURAL CHOLESTEROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NATURAL CHOLESTEROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SYNTHETIC CHOLESTEROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SYNTHETIC CHOLESTEROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ALC-0315, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ALC-0315, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DLIN-MC3-DMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DLIN-MC3-DMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SM-102, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY SM-102, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DMG-PEG, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DMG-PEG, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DSPE-PEG, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DSPE-PEG, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DSPC, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DSPC, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TIER ONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TIER ONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TIER TWO, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY TIER TWO, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOPS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOTAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOTAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOTMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY DOTMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NEUTRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL RNA-LNP FORMULATION MARKET SIZE, BY NEUTRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS RNA-LNP FORMULATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES RNA-LNP FORMULATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 223. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. CANADA RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 226. CANADA RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 227. CANADA RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 228. CANADA RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 229. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 230. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 231. CANADA RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 232. CANADA RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 233. CANADA RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. CANADA RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. CANADA RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 236. CANADA RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 237. CANADA RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 238. CANADA RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 239. CANADA RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 240. CANADA RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 241. CANADA RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 242. CANADA RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 243. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 244. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 245. CANADA RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 246. CANADA RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 247. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 248. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 249. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 250. CANADA RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 251. CANADA RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. CANADA RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 254. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 255. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 256. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 257. CANADA RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 258. CANADA RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 259. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 260. CANADA RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 261. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 264. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 265. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 266. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 267. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 268. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 269. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 270. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 271. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 272. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 273. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 274. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 275. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 276. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 277. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 278. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 279. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 280. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 281. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 282. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 283. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 284. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 285. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 286. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 287. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 288. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 289. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 292. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 293. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 294. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 295. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 296. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 297. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 298. MEXICO RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY SIRNA, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 315. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 316. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 317. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2018-2024 (USD MILLION)
TABLE 318. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY LIPID COMPOSITION, 2025-2030 (USD MILLION)
TABLE 319. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2018-2024 (USD MILLION)
TABLE 320. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CHOLESTEROL, 2025-2030 (USD MILLION)
TABLE 321. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2018-2024 (USD MILLION)
TABLE 322. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY IONIZABLE LIPID, 2025-2030 (USD MILLION)
TABLE 323. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2018-2024 (USD MILLION)
TABLE 324. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PEG LIPIDS, 2025-2030 (USD MILLION)
TABLE 325. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2018-2024 (USD MILLION)
TABLE 326. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY PHOSPHOLIPID, 2025-2030 (USD MILLION)
TABLE 327. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 330. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 331. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2018-2024 (USD MILLION)
TABLE 332. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CHARGE, 2025-2030 (USD MILLION)
TABLE 333. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2018-2024 (USD MILLION)
TABLE 334. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY ANIONIC, 2025-2030 (USD MILLION)
TABLE 335. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2018-2024 (USD MILLION)
TABLE 336. BRAZIL RNA-LNP FORMULATION MARKET SIZE, BY CATIONIC, 2025-2030 (USD MILLION)
TABLE 337. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 338. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 339. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2018-2024 (USD MILLION)
TABLE 340. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY MIRNA, 2025-2030 (USD MILLION)
TABLE 341. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 342. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 343. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2018-2024 (USD MILLION)
TABLE 344. ARGENTINA RNA-LNP FORMULATION MARKET SIZE, BY PDNA, 2025-2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this RNA-LNP Formulation market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza Group Ltd.
  • Catalent, Inc.
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Evonik Industries AG
  • Croda International Plc
  • CordenPharma International GmbH
  • Recipharm AB
  • Polymun Scientific GmbH

Related Reports

circRNA-LNP Formulation Market - Global Forecast 2025-2030 - Product Image

circRNA-LNP Formulation Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Lipid Nanoparticles Market by Product (Ionizable Lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (SiRNA, MRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029 - Product Image

Lipid Nanoparticles Market by Product (Ionizable Lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (SiRNA, MRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029

  • Report
  • 317 Pages
  • Global
From
Lipid Nanoparticle Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033 - Product Image

Lipid Nanoparticle Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Lipid Nanoparticle Market Size, Share & Trends Analysis Report by LNP (Liposomes, Nanostructured Lipid Carriers), Molecule (MRNA, SiRNA), Application, Indication, End Use, Region, with Growth Forecasts, 2025-2030 - Product Image

Lipid Nanoparticle Market Size, Share & Trends Analysis Report by LNP (Liposomes, Nanostructured Lipid Carriers), Molecule (MRNA, SiRNA), Application, Indication, End Use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Lipid Nanoparticle Manufacturing Market Report and Forecast 2025-2034 - Product Image

Lipid Nanoparticle Manufacturing Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.